General form of registration statement for all companies including face-amount certificate companies

11. Stockholders' Equity (Details Narrative)

v3.5.0.1
11. Stockholders' Equity (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Prepayment on acquisition $ 3,744,517   $ 3,744,517 $ 0
Research and development expense $ 429,281 $ 1,035,083 $ 3,434,016 $ 6,323,896
SynBio 2014 Warrant [Member]        
Warrant issued       204,394
Warrant exercise price per share       $ 25.41
Warrants exercised     0 0
SynBio Partner Warrants [Member] | SynBio 2014 Warrant [Member]        
Warrant issued       9,697
Warrants exercised     0 0
Serum Institute 2014 Warrant [Member]        
Warrant issued       96,970
Fair value of warrant at date of grant       $ 480,000
Warrant exercise price per share       $ 25.41
Serum Institute 2014 Warrant [Member] | Serum Institute Partner Warrants [Member]        
Warrant issued       4,849
Fair value of warrant at date of grant       $ 24,000
Warrants exercised     0 0
Warrant expense     $ 706,500 $ 0
Asset Purchase Agreement [Member]        
Prepayment on acquisition     $ 3,744,517  
Issuance of common stock in connection with pending asset acquisition, shares     333,334  
Non-Employee Director [Member]        
Warrant issued       48,485
Fair value of warrant at date of grant       $ 240,000
Warrant exercise price per share       $ 25.41
Consultant [Member]        
Warrant issued     25,243  
Fair value of warrant at date of grant     $ 227,000  
Warrant exercise price per share     $ 25.41  
Warrant expense     $ 227,000  
Baxalta [Member]        
Stock issued for equity investment, shares     324,097  
Stock issued for equity investment, amount     $ 10,000,000  
Non-Employee Director [Member]        
Warrant expense       $ 240,000